Source comparison
CJC-1295 No DAC for Women Over 40: Comparison
Half-Life ~30 minutes 6–8 days 2–4 hours (SC injection) 20–30 minutes No DAC requires multiple daily doses but preserves natural pulsatility; DAC simplifies dosing but risks blunted receptor sensitivity over time Dosing Frequency 2–3× daily 1–2× weekly Daily i
This comparison does not assign a generated winner or score.
- Half-Life
- ~30 minutes
- 6–8 days
- 2–4 hours (SC injection)
- 20–30 minutes
- No DAC requires multiple daily doses but preserves natural pulsatility; DAC simplifies dosing but risks blunted receptor sensitivity over time
- Dosing Frequency
- 2–3× daily
- 1–2× weekly
- Daily injection
- Women over 40 benefit most from protocols that align with circadian GH patterns. No DAC supports this; weekly dosing with DAC does not
- Receptor Target
- GHRH receptor (pituitary)
- Direct GH replacement (no receptor involved)
- Ghrelin receptor (hypothalamus + pituitary)
- GHRH analogues amplify existing pulses; GHRPs suppress somatostatin. Stacking both addresses the dual pathway
- Effect on Endogenous Production
- Preserves and amplifies natural GH pulses
- Preserves pulses but may blunt response with chronic use
- Shuts down endogenous production entirely
- Preserves and amplifies pulses, suppresses somatostatin
- Preservation of feedback loops is critical for long-term metabolic health in women over 40
- Somatostatin Sensitivity
- Cannot override elevated somatostatin tone
- Not applicable (bypasses GHRH pathway)
- Actively suppresses somatostatin signalling
- Perimenopausal women often have elevated somatostatin. Monotherapy CJC-1295 underperforms without GHRP co-administration
- IGF-1 Elevation
- Moderate (pulse-dependent)
- Moderate to high (sustained)
- High (dose-dependent)
- Low to moderate
- IGF-1 >250 ng/mL correlates with improved lean mass outcomes in women over 40; synthetic GH achieves this fastest but with highest adverse event risk